文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

NBTXR3纳米颗粒增强放疗克服抗PD1耐药并诱发远隔效应

Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-07-06

该研究在抗PD1耐药与敏感的小鼠转移性肺癌模型中,将瘤内注射NBTXR3、局部放疗(12 Gy×3次)与全身抗PD1联合,发现三联方案显著延缓照射野内外肿瘤生长,并在耐药模型中重塑未照射肿瘤的免疫微环境、增加CD8+ T细胞并改变T细胞受体库。

要点

  • NBTXR3联合放疗与抗PD1可延缓抗PD1耐药及敏感肺癌小鼠的照射与未照射肿瘤生长。
  • 在耐药模型中,NBTXR3可激活多条免疫通路、增加CD8+ T细胞并重塑TCR库。
  • 该策略在抗PD1敏感与耐药肺癌中均诱发远隔效应,提示可不受免疫治疗敏感性限制。

核心结论

  • NBTXR3联合局部放疗与全身抗PD1能在抗PD1敏感和耐药的转移性肺癌小鼠中诱发显著远隔效应。

研究设计与样本

  • 研究为小鼠肺癌模型实验:雌性129Sv/Ev小鼠右腿接种原发瘤、左腿接种继发瘤,使用344SQ抗PD1耐药(344SQR)与敏感(344SQP)细胞。
  • 原发瘤于第7天瘤内注射NBTXR3,第8、9、10天接受12 Gy照射,并腹腔注射抗PD1共6次。
  • 采用RNA测序分析T细胞受体库、免疫组化检测CD8 T细胞浸润、NanoString分析免疫通路活性。

主要发现

  • NBTXR3联合局部放疗与全身抗PD1的三联方案在344SQP和344SQR模型中均显著延缓照射与未照射肿瘤的生长。
  • 在344SQR耐药模型中,NBTXR3触发多条免疫通路激活、增加CD8+ T细胞数量并改变未照射肿瘤的T细胞受体库。

关键数值与推荐

  • 原发瘤照射剂量为12 Gy,于第8、9、10天分次给予。
  • 抗PD1共腹腔注射6次。
  • NBTXR3于第7天瘤内注射。

临床怎么用

  • 该策略提示对免疫治疗敏感或耐药的转移性肺癌患者,NBTXR3增强放疗联合抗PD1可能克服耐药并诱导远隔效应。
  • 临床转化前需进一步验证安全性与有效性。

局限性

  • 研究为小鼠模型,结果不能直接外推至患者。
  • 原文未报告样本量、P值及具体免疫通路名称等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation combined with PD1 blockade offers significant treatment benefits in several tumor types; however, anti-PD1 resistance precludes such benefits in many cases. Here we attempted to overcome anti-PD1 resistance by combining localized radiation with a radioenhancing nanoparticle (NBTXR3) and systemic anti-PD1 treatment to achieve abscopal effects in an anti-PD1-resistant mouse model of lung cancer. METHODS AND MATERIALS: Female 129Sv/Ev mice were inoculated with 344SQ anti-PD1-resistant (344SQR) or anti-PD1-sensitive (344SQP) metastatic lung cancer cells in the right leg on day 0 ("primary" tumor) and the left leg on day 4 ("secondary" tumor). Primary tumors were injected intratumorally with NBTXR3 on day 7 and were irradiated with 12 Gy on days 8, 9, and 10. Mice were given 6 intraperitoneal injections of anti-PD1. T cell receptor repertoire was analyzed in tumor samples with RNA sequencing, infiltration of CD8 T cells with immunohistochemical staining, and activities of various immune pathways with NanoString analysis. RESULTS: The triple combination of NBTXR3 with localized radiation and systemic anti-PD1 significantly delayed the growth of both irradiated and unirradiated tumors in both 344SQP and 344SQR tumor models. NBTXR3 remodeled the immune microenvironment of unirradiated tumors by triggering the activation of various immune pathways, increasing the number of CD8+ T cells, and modifying the T cell receptor repertoire in the 344SQR tumor model. CONCLUSIONS: The ability of NBTXR3 to evoke significant abscopal effects in both anti-PD1-sensitive and anti-PD1-resistant lung cancers could open the possibility of its use for treating patients with metastatic lung cancer regardless of sensitivity (or resistance) to immunotherapies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hu Y, Paris S, Barsoumian H, et al. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. Int J Radiat Oncol Biol Phys. 2021. PMID: 34242713. doi:10.1016/j.ijrobp.2021.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。